Sign in Subscribe
Class action lawsuits

Class Action Lawsuit Filed Against Cytokinetics, Incorporated

Strategic Insights

— 1 min read

Investors in Cytokinetics, Incorporated have been notified of a class action securities lawsuit alleging securities fraud between December 27, 2023, and May 6, 2025. The lawsuit claims that the Company made false and misleading statements regarding the timeline for the New Drug Application submission and approval process for aficamten. Specifically, defendants represented that the Company expected approval from the FDA in the second half of 2025, based on a September 26, 2025 PDUFA date, and failed to disclose material risks related to the Company's failure to submit a Risk Evaluation and Mitigation Strategy that could delay the regulatory process.

Key Takeaways:

  • The lawsuit seeks to recover losses on behalf of Cytokinetics investors who were adversely affected by alleged securities fraud between December 27, 2023, and May 6, 2025.
  • Defendants allegedly made false and misleading statements regarding the timeline for the New Drug Application submission and approval process for aficamten.
  • The lawsuit claims that defendants failed to disclose material risks related to the Company's failure to submit a Risk Evaluation and Mitigation Strategy that could delay the regulatory process.
  • On May 6, 2025, it was revealed that the Company had multiple pre-NDA meetings with the FDA discussing safety monitoring and risk mitigation but chose to submit the NDA without a REMS.
  • As a result of defendants' false and misleading statements, class members purchased Cytokinetics' common stock at artificially inflated prices and suffered significant losses when the truth was revealed.
  • Investors have until November 17, 2025, to request that the Court appoint them as lead plaintiff.
  • There is no cost or obligation to participate in the lawsuit, and a team of over 70 employees at Levi & Korsinsky will serve clients in the case.

Statistics:

  • The lawsuit seeks to recover losses on behalf of Cytokinetics investors who were adversely affected by alleged securities fraud between December 27, 2023, and May 6, 2025.
  • The Company allegedly made false and misleading statements regarding the timeline for the New Drug Application submission and approval process for aficamten.
  • The PDUFA date for the NDA submission was originally scheduled for September 26, 2025.
  • Class members purchased Cytokinetics' common stock at artificially inflated prices and suffered significant losses when the truth was revealed.

Sources:

  • Levi & Korsinsky, LLP press release, October 17, 2025
  • [PRNewswire article]
  • US Securities and Exchange Commission (SEC) guidelines for securities fraud cases
  • Securities Class Action Services' Top 50 Report

Read more